Progress in human tumour immunology and immunotherapy

Studies of the administration of interleukin-2 to patients with metastatic melanoma or kidney cancer have shown that immunological manipulations can mediate the durable regression of metastatic cancer. The molecular identification of cancer antigens has opened new possibilities for the development o...

Full description

Saved in:
Bibliographic Details
Published in:Nature (London) 2001-05, Vol.411 (6835), p.380-384
Main Author: Rosenberg, Steven A
Format: Article
Language:English
Subjects:
Antigens, Neoplasm - immunology
Cancer
Cancer Vaccines - immunology
Humans
Immunization
Immunology
Immunotherapy
Interleukin-2 - immunology
Interleukin-2 - therapeutic use
Kidneys
Lymphocytes
Melanoma
Molecular biology
Neoplasms - immunology
Neoplasms - prevention & control
Neoplasms - therapy
Neoplasms - virology
Peptides
T-Lymphocytes - immunology
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Studies of the administration of interleukin-2 to patients with metastatic melanoma or kidney cancer have shown that immunological manipulations can mediate the durable regression of metastatic cancer. The molecular identification of cancer antigens has opened new possibilities for the development of effective immunotherapies for patients with cancer. Clinical studies using immunization with peptides derived from cancer antigens have shown that high levels of lymphocytes with anti-tumour activity can be raised in cancer-bearing patients. Highly avid anti-tumour lymphocytes can be isolated from immunized patients and grown in vitro for use in cell-transfer therapies. Current studies are aimed at understanding the mechanisms that enable the cancer to escape from immune attack.
ISSN:0028-0836
1476-4687
DOI:10.1038/35077246